Insmed Incorporated (NASDAQ:INSM - Get Free Report) saw strong trading volume on Friday . 10,333,584 shares traded hands during trading, an increase of 352% from the previous session's volume of 2,285,543 shares.The stock last traded at $69.34 and had previously closed at $68.96.
Analysts Set New Price Targets
A number of brokerages have issued reports on INSM. Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and set a $90.00 target price on shares of Insmed in a research note on Tuesday, April 22nd. Stifel Nicolaus dropped their price target on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $94.00.
Read Our Latest Stock Analysis on INSM
Insmed Price Performance
The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm's 50-day moving average price is $74.38 and its 200-day moving average price is $73.57. The stock has a market capitalization of $12.77 billion, a PE ratio of -12.54 and a beta of 1.07.
Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, equities analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares of the company's stock, valued at approximately $7,766,640. This trade represents a 48.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 6,830 shares of the company's stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares in the company, valued at $16,412,107.84. This trade represents a 2.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 471,797 shares of company stock valued at $37,621,239 over the last three months. 3.00% of the stock is owned by company insiders.
Institutional Investors Weigh In On Insmed
A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Elequin Capital LP purchased a new position in shares of Insmed during the fourth quarter worth approximately $28,000. Steward Partners Investment Advisory LLC increased its holdings in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the period. NBC Securities Inc. bought a new stake in Insmed during the 1st quarter valued at $49,000. V Square Quantitative Management LLC lifted its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares during the period. Finally, Spire Wealth Management bought a new position in shares of Insmed during the 4th quarter worth $47,000.
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Recommended Stories
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
